VKTX

MKT CAP:$4B

Viking Therapeutics, Inc.

Market Cap

$4B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$32.80-$2.62 (-7.40%)

Apr 23, 2026

Company Details

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor...

CEO

Brian Lian

IPO Date

Apr 28, 2015

Website

www.vikingtherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$360M

EPS (Diluted)

-$3.18

Free Cash Flow

-$279M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Feb 11, 2026

$0EPS -$3.19

Q4 2025

Feb 11, 2026

$0EPS -$1.38

Q3 2025

Oct 22, 2025

$0EPS -$0.81

Q2 2025

Jul 23, 2025

$0EPS -$0.58

Q1 2025

Apr 24, 2025

$0EPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$16M
Q2 22	$0	$0	-$18M
Q3 22	$0	$0	-$16M
Q4 22	$0	$0	-$20M
Q1 23	$0	$0	-$21M
Q2 23	$0	$0	-$24M
Q3 23	$0	$0	-$27M
Q4 23	$0	$0	-$29M
Q1 24	$0	$0	-$34M
Q2 24	$0	$0	-$34M
Q3 24	$0	$0	-$37M
Q4 24	$0	$0	-$46M
Q1 25	$0	$0	-$55M
Q2 25	$0	$0	-$75M
Q3 25	$0	-$114.0K	-$99M
Q4 25	$0	-$94.0K	-$165M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$11M	-$11M
Q2 22	-$13M	-$13M
Q3 22	-$13M	-$13M
Q4 22	-$11M	-$11M
Q1 23	-$25M	-$25M
Q2 23	-$11M	-$11M
Q3 23	-$20M	-$20M
Q4 23	-$18M	-$18M
Q1 24	-$6M	-$6M
Q2 24	-$29M	-$29M
Q3 24	-$22M	-$22M
Q4 24	-$31M	-$31M
Q1 25	-$52M	-$52M
Q2 25	-$47M	-$47M
Q3 25	-$94M	-$94M
Q4 25	-$85M	-$85M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+14.2%
Q2 22	—	+13.4%
Q3 22	—	+20.8%
Q4 22	—	+62.1%
Q1 23	—	+26.4%
Q2 23	—	+34.6%
Q3 23	—	+68.3%
Q4 23	—	+44.4%
Q1 24	—	+65.9%
Q2 24	—	+43.4%
Q3 24	—	+34.1%
Q4 24	—	+57.9%
Q1 25	—	+62.8%
Q2 25	—	+119.0%
Q3 25	—	+169.6%
Q4 25	—	+256.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$2M	—
Q4 22	$2M	—
Q1 23	$4M	—
Q2 23	$5M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$8M	—
Q2 24	$7M	—
Q3 24	$9M	—
Q4 24	$6M	—
Q1 25	$11M	—
Q2 25	$14M	—
Q3 25	$7M	—
Q4 25	$9M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$13M	$4M
Q2 22	$14M	$4M
Q3 22	$12M	$4M
Q4 22	$16M	$4M
Q1 23	$11M	$10M
Q2 23	$14M	$10M
Q3 23	$18M	$9M
Q4 23	$21M	$9M
Q1 24	$24M	$10M
Q2 24	$24M	$10M
Q3 24	$23M	$14M
Q4 24	$31M	$15M
Q1 25	$41M	$14M
Q2 25	$60M	$14M
Q3 25	$90M	$9M
Q4 25	$153M	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$12M	$172M	$185M
Q2 22	$16M	$153M	$169M
Q3 22	$29M	$126M	$155M
Q4 22	$37M	$119M	$155M
Q1 23	$18M	$117M	$136M
Q2 23	$70M	$323M	$393M
Q3 23	$37M	$339M	$376M
Q4 23	$56M	$307M	$362M
Q1 24	$196M	$767M	$963M
Q2 24	$44M	$898M	$942M
Q3 24	$50M	$880M	$930M
Q4 24	$27M	$876M	$903M
Q1 25	$38M	$814M	$852M
Q2 25	$34M	$774M	$808M
Q3 25	$100M	$614M	$715M
Q4 25	$166M	$540M	$706M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	77M	+0.7%	+3.5%
Q2 22	77M	-0.5%	-1.1%
Q3 22	77M	-0.7%	-1.9%
Q4 22	77M	+0.1%	-0.4%
Q1 23	78M	+2.3%	+1.2%
Q2 23	99M	+26.4%	+28.5%
Q3 23	100M	+0.8%	+30.5%
Q4 23	100M	+0.3%	+30.7%
Q1 24	103M	+3.3%	+32.0%
Q2 24	110M	+6.7%	+11.5%
Q3 24	111M	+0.5%	+11.1%
Q4 24	111M	+0.4%	+11.2%
Q1 25	112M	+0.7%	+8.3%
Q2 25	112M	+0.1%	+1.6%
Q3 25	112M	+0.2%	+1.3%
Q4 25	114M	+1.5%	+2.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	17
Q2 22	$0	17
Q3 22	$0	17
Q4 22	$0	21
Q1 23	$0	21
Q2 23	$0	21
Q3 23	$0	21
Q4 23	$0	27
Q1 24	$0	27
Q2 24	$0	27
Q3 24	$0	27
Q4 24	$0	36
Q1 25	$0	36
Q2 25	$0	36
Q3 25	$0	36
Q4 25	$0	33

Revenue / Employee